Summary
Work History
Education
Skills
Affiliations
Accomplishments
References
Timeline
Generic
David Augeri

David Augeri

Princeton

Summary

Accomplished Principal Consultant at DJ Augeri Pharma Consulting, LLC, with a proven track record in drug development and clinical trial management. Expert in regulatory compliance and analytical chemistry, having authored multiple patents and led successful IND submissions. Renowned for fostering cross-functional collaboration and driving innovative solutions in pharmaceutical research.

Work History

Principal Consultant

DJ Augeri Pharma Consulting, LLC
Princeton
01.2012 - Current
  • Initiated academic collaboration with professors at UNC Chapel Hill and NIDA, NIH in 2023.
  • Designed novel DPP1 inhibitor for Insmed in 2022, utilizing PDB file from AstraZeneca's brensocatib.
  • Assisted Kodikaz Therapeutics in developing radiolabeled DNA vaccine for in vivo cancer study.
  • Consulted for Exion Laboratories to develop proprietary LPEI polymer-based products.
  • Authored ICH-guided Phase 2a clinical trial protocol for oncology group at Capital Health Hospitals.
  • Managed three CMC campaigns to produce 1.0 KG small molecule API for IND filing.
  • Provided expert consultation in 18 legal cases since 2014 on various drug inhibitors and formulations.
  • Conducted GAP analysis of equipment compliance with FDA guidelines for clinical trials.

SAB Member

Urania Therapeutics
Strasburg
01.2021 - 01.2023
  • Reviewed the program portfolio, raised questions, evaluated progress, and offered guidance.

Med Chem and CMC Consultant FTE

Rapafusyn
Baltimore (consulted Remote Princeton, NJ
03.2022 - 11.2022
  • Redesigned the library to infuse heterocyclic congeners of Alpha Aas (such as subst.). Pyrimidine for phenyl of Phe, N-Me pyrazole for phenylglycine, substituted a morpholine ring for pyrrolidine in a D-Pro, and all three reduced macrocycle CLogP from 8.87 to 4.92.
  • Managed the full spectrum of CMC while steering the synthesis of 1.0 kilo API under both GLP and GMP guidelines.
  • Oversaw CMC facets of Phase 1, GLP, and GMP-API for the rapadocin drug, facilitating the FIM study post-IND submission.
  • Organized CDMOs, scrutinized chemistry capabilities, timelines, cost-efficiency, drug substance production from API, IV formulations, delivery dates, and analytical chemistry in compliance with all eCTD-driven documents of IND for Modules 2 and 3, part of Module 4.

Professor of Synthetic Organic/Medicinal Chemistry

State Univ of New Jersey - Rutgers
Piscataway
01.2013 - 02.2020
  • Taught graduate synthesis course(s). - Asymmetric Organic Chemistry, pericyclic reaction mechanisms, and polycyclic ring construction strategies.
  • Terpene indole alkaloids illustrate nature’s way to diversify the shape and physical properties of isomeric compounds by varied placement of the bridgehead nitrogen. Particular attention was paid to strychnos (the MacMillan and the Overman synthesis of strychnine), aspidosperma (aspidospermidine, tabersonine), iboga (corynanthe), and the Woodward landmark synthesis of the yohimbine alkaloid (reserpine). Conformational analysis is carefully covered for select syntheses.
  • Fostered relationships with industry professionals and research organizations to form collaborations.
  • Collaborated with PIs; co-authored NIH R01–5 funded R01s ($2.8–3.1 million), 1 funded R21, and 1 funded DoD grant ($2.8 million).

Director of Medicinal Chemistry

Lexicon Pharmaceuticals Inc.
Princeton
06.2003 - 08.2012
  • Led teams of 16 to 18 scientists (PhDs, MS) who achieved 3 INDs for RA (rheumatoid arthritis) and MS (multiple sclerosis).
  • Mentored the group in the optimization of potency and physical properties with a single structural change; analogs showed higher binding affinity and improved features of permeability, EC50, and PK.
  • Mentoring PhD journal manuscripts and external presentations.

Research Investigator

Bristol Myers Squibb
Princeton
09.1999 - 06.2003
  • Invented ONGLYZA (saxagliptin), FDA Approval 2009 as DPP4 TD2 |Augeri et al., J. Med. Chem., 2005, 48, 5025-5037.

Research Investigator

AbbVie
North Chicago
05.1995 - 09.1999
  • Research Investigator, NMR Group, Oncology-Fragment-Based Drug Discovery, Abbott Laboratories, Abbott Park, IL.
  • Invented a lead molecule that launched AbbVie Venclexta—NMR structure-based design of a bcl-2 inhibitor (acylsulfonamide) that initiated a 15-person effort that discovered VENCLEXTA (venetoclax, bcl-2 inhibitor, CML, and B-cell cancer).
  • published seven papers that highlighted structure-based design and fragment-based methods fundamental to my approach to generating a lead molecule (over 6,500 citations for the seven papers).

USN Active Duty

United States Navy, 2nd Recon. Div. USMC, NC,
Camp Lejeune (Camp Johnson)
07.1977 - 07.1983
  • 1977–1981 Embedded 2nd Recon. Div. USMC, Camp Lejeune, NC TAC/FAC Officer, and Field Medic.
  • 1981-1983, Pharmacy Technician, US Naval Submarine Medical Center, US Sub Base, Groton, CT.

Education

NIH Postdoctoral Fellow - Natural Products Chemistry

Princeton University
Princeton, NJ
04-1995

Ph.D. - Synthetic Organic Chemistry

University of California, Irvine
Irvine, CA
12-1992

Skills

  • Drug development
  • Clinical trial management
  • Regulatory compliance
  • Analytical chemistry
  • Project management
  • Data analysis
  • Industry Leadership Engagement
  • Data-driven Decision Making
  • Efficient and Effective Lead Optimization
  • OptPK-PD
  • Drug Discovery
  • Innovation
  • Drug Design
  • Multidisciplinary Team Leadership
  • Cross-Functional Collaboration
  • Inventor listed on >60 issued US Patents
  • Author of >20 Provisional Patent Applications
  • Patent and IP Expert Litigation Expert
  • Expert Witness and Testimony
  • Pharmaceutical & FDA Compliance
  • Radiochemistry Synthesis and Studies
  • Module 2/4 eCTD
  • NIH-NSF Funded Investigator
  • Phase I CMC (10 kg API)
  • Dotmatics, Data Warrior, and StarDrop

Affiliations

  • American Chemical Society since 1987; Division of Organic Chemistry; Division of Medicinal Chemistry
  • Maintains fitness of expert rock climber, 5.11a+/Average 8 KM run / calendar day 4 yrs; Rigorous weight lifting 4xweekly

Accomplishments

  • UC-Irvine PhD, Synthetic Organic Chemistry – prepared deoxypolypropionate subunits using a novel hydrazone-mediated diastereoselective alkylation to generate 1,3-skipped syn-or 1,3-skipped anti-dialkylated chains.
  • Princeton University NIH Postdoctoral Fellowship – Natural Product Synthesis – prepared calicheamicin oligosaccharide and measured the associated DNA binding affinity.
  • FDA Drug Discovery – AbbVie - Designed the acylsulfonamide lead directly from a ternary NMR structure that launched the Venclexta (bcl-2, cancer) project. Venclexta contains the acylsulfonamide linker with the necessary geometry and site1/site2 connection points to properly orient it in the Bcl-2 BH3 groove to inhibit bcl-2. FDA Venclexta 2015.
  • 2002 Bristol Myers Squibb names Saxagliptin "Molecule of the Year."
  • FDA Drug Discovery – Bristol-Myers Squibb, discovery of saxagliptin (Onglyza, DPP4 inhibitor, T2DM, FDA2009).
  • Awarded 5 funded NIH R01 grant proposals
  • 1 DoD grant proposal
  • published 47 peer-reviewed journal articles
  • inventor listed on > 60 issued US Patents
  • Pharmacyclics v. Acerta, 2014 - 2016 (BTK, acalabrutinib/ibrutinib expert consultant)
  • Merck (sitagliptin ANDA, expert witness 2018 – 2019)
  • BMS (saxagliptin ANDA, expert witness 2018 – 2019
  • Empagliflozin-BI vs. Zydus. Expert regarding Jardiance. 2019
  • AstraZeneca 2020-2022 (saxagliptin ANDA; Mylan, expert for Onglyza)
  • ANDA Trazodone, 2020 – 2021 Expert Witness
  • University of Michigan. Expert regarding Genzyme sphingosine-1-phosphate and ceramide signaling, 2020 – 2021 Expert Witness
  • Merck. Canada ANDA. Expert regarding Januvia. 2021 – 2023 Expert Witness
  • Linagliptin vs. B.I., Canada. 2021 – 2023 Expert Witness
  • Amgen Canada Inc. & Onyx Therapeutics Inc. v. Dr. Reddy's Laboratories Ltd. 2024, AitkenKlee Expert Witness

References

  • Dr. Marion Chiattello, Chief Technology Officer, Exion Labs, 2627 Abraham Drive, Cedar Falls, Iowa 50613; marion.chiattello@exionlabs.com
  • Dr. Jeffrey Bagdanoff, Principal Investigator, Novartis Pharmaceutics, Cambridge, Massachusetts; jeffrey.bagdanoff@novartis.com
  • Dr. James Tarver, Director of Medical Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; james.tarver.phd@gmail.com

Timeline

Med Chem and CMC Consultant FTE

Rapafusyn
03.2022 - 11.2022

SAB Member

Urania Therapeutics
01.2021 - 01.2023

Professor of Synthetic Organic/Medicinal Chemistry

State Univ of New Jersey - Rutgers
01.2013 - 02.2020

Principal Consultant

DJ Augeri Pharma Consulting, LLC
01.2012 - Current

Director of Medicinal Chemistry

Lexicon Pharmaceuticals Inc.
06.2003 - 08.2012

Research Investigator

Bristol Myers Squibb
09.1999 - 06.2003

Research Investigator

AbbVie
05.1995 - 09.1999

USN Active Duty

United States Navy, 2nd Recon. Div. USMC, NC,
07.1977 - 07.1983

NIH Postdoctoral Fellow - Natural Products Chemistry

Princeton University

Ph.D. - Synthetic Organic Chemistry

University of California, Irvine

Similar Profiles

CREATE PROFILE
David Augeri